Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer

Дата публикации: 28-07-2026 00:00:00

This randomized trial assesses the effect of ivonescimab added to chemotherapy on overall survival among patients with EGFR-variant non–small cell lung cancer (NSCLC) who had disease progression with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC	0	5	30-06-2026
2	Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions	0	5	23-06-2026
3	Troponin Screening and Major Cardiovascular Adverse Events During ICI Therapy	0	7.02	21-07-2026
4	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
5	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
6	EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan	0	5	26-06-2026
7	Lung transplant dramatically improves survival for patients with terminal lung cancer, study finds	7	8	08-07-2026
8	FDA approves Jideytro for previously treated ROS1-positive NSCLC	0	15.41	23-07-2026
9	Racial Variations in Secondary Treatment and Survival in Prostate Cancer	0	7.35	21-07-2026
10	Race, Secondary Treatment, and Survival in Localized Prostate Cancer	0	5.24	21-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10. Источник: jamanetwork.com.